This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Walgreens Discusses Success Of Community Pharmacy Programs In Improving Patient Medication Adherence

Walgreens (NYSE: WAG) (Nasdaq:WAG) recently presented the latest research on how community pharmacy programs, as well as new adherence models and metrics, can help drive better medication adherence. The research, presented at the World Congress Summit in Philadelphia last Friday, demonstrates the company’s success in improving patient medication adherence by developing an infrastructure that tracks patient level adherence and uses predictive modeling along with risk stratification to identify patient patterns.

Kristi Rudkin, PharmD, senior director of product development for Walgreens, and Michael S. Taitel, PhD, Walgreens senior director of clinical outcomes and analytic services, discussed the research findings along with product-specific interventions focused on empowering patients to better self-manage their condition. The discussion also examined the latest research related to new-to-therapy counseling and automated Interactive Voice Responses (IVR) refill reminders.

“Medication non-adherence is one of the greatest and most costly barriers in treating illness today,” Rudkin said. “By developing programs and services that can help reduce these barriers, and examining ways to drive cost savings and improved health outcomes through better adherence, we can help more people get, stay and live well.”

New-to-therapy patients often face adherence challenges while trying to learn a new medication regimen. A retrospective cohort study assessing the impact of pharmacist-led, face-to-face counseling in new-to-therapy statin patients found that compared to usual pharmacy care, those patients receiving face-to-face counseling had 7.2 percent higher adherence. 1

Forgetfulness can also be a contributor to non-adherence. In a pilot program, automated refill reminders (ARR) significantly improved patient adherence to medications used to treat chronic conditions. Patients who received automated Interactive Voice Responses (IVR) telephonic reminders had a significantly higher medication possession ratio (MPR) compared with patients who did not receive reminders. Additionally, the persistence for the intervention was nearly eight days longer than that of the control group.

“Helping patients improve their medication adherence is a challenge for providers, payers and many others within the health care system,” Taitel said. “We’ve demonstrated the effectiveness of several programs and initiatives - including our new to therapy program, automated refill reminder calls. Integrating predictive modeling and risk stratification will help us be even more effective at driving better adherence, and ultimately better health outcomes.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs